Home » Services » Preclinical studies » Efficacy studies » Ocular Neurodegeneration
Ocular neurodegeneration


  • retinal ganglion cell loss in optic nerve clamping model
  • retinal ganglion cell loss in model of elevated intraocular pressure (high IOP or HIOP)
  • photoreceptor apoptosis in animal models of blue light damage (LD) retinal degeneration


  • dry AMD
  • geographic atrophy
  • glaucoma
  • central retinal artery or vein occlusion (CRAO, CRVO)

Administrations: topical ocular application, intravenous, intraperitoneal, intravitreal, subconjunctival, systemic

Animals: rats



  • electroretinography (ERG)
  • histology RPE or retinal outer nuclear layer (ONL) thickness

Positive controls: brimonidine, DMTU or 8-OH-DPAT


If you need more information on Iris Pharma’s animal models of Ocular Neurodegeneration for the development of your new neuroprotective treatment, please contact us at info@iris-pharma.com or call 33 4 93 59 49 59